CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Phase 1

Active, not recruiting

Conditions: Primary Myelofibrosis

Interventions: Drug: Fedratinib

First Posted Date: 2020-06-25

Last Posted Date: 2024-09-30

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT04446650

Locations: 🇯🇵
Local Institution - 016, Osaka, Japan
🇯🇵
Local Institution - 014, Sapporo, Japan
🇯🇵
Local Institution - 021, Suwa, Nagano, Japan

and more 18 locations

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: CC-99282
Drug: Obinutuzumab

First Posted Date: 2020-06-16

Last Posted Date: 2024-07-25

Lead Sponsor: Celgene

Target Recruit Count: 16

Registration Number: NCT04434196

Locations: 🇺🇸
Local Institution - 104, Columbus, Ohio, United States
🇺🇸
Local Institution - 106, Boston, Massachusetts, United States
🇺🇸
Local Institution - 101, Portland, Oregon, United States

and more 12 locations

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: CC-94676
Drug: CC1083611
Drug: CC1083610

First Posted Date: 2020-06-11

Last Posted Date: 2024-10-26

Lead Sponsor: Celgene

Target Recruit Count: 250

Registration Number: NCT04428788

Locations: 🇺🇸
Local Institution - 116, Stanford, California, United States
🇺🇸
Local Institution - 122, Washington, District of Columbia, United States
🇺🇸
Local Institution - 103, Sarasota, Florida, United States

and more 16 locations

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-93538

First Posted Date: 2020-05-04

Last Posted Date: 2021-09-28

Lead Sponsor: Celgene

Target Recruit Count: 52

Registration Number: NCT04373187

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Phase 2

Completed

Conditions: Neoplasms

Interventions: Drug: CC-90011
Drug: Nivolumab

First Posted Date: 2020-04-17

Last Posted Date: 2025-01-22

Lead Sponsor: Celgene

Target Recruit Count: 92

Registration Number: NCT04350463

Locations: 🇺🇸
Local Institution - 107, Fort Sam Houston, Texas, United States
🇺🇸
Local Institution - 105, Canton, Ohio, United States
🇺🇸
Local Institution - 110, Houston, Texas, United States

and more 34 locations

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: CC-90009
Drug: Gilteritinib
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2020-04-07

Last Posted Date: 2024-05-31

Lead Sponsor: Celgene

Target Recruit Count: 22

Registration Number: NCT04336982

Locations: 🇺🇸
Local Institution - 104, San Francisco, California, United States
🇺🇸
Local Institution - 103, Boston, Massachusetts, United States
🇨🇦
Local Institution - 201, Toronto, Ontario, Canada

and more 11 locations

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Phase 1

Terminated

Conditions: Glioblastoma

Interventions: Drug: CC-90010
Drug: Temozolomide
Radiation: Radiotherapy

First Posted Date: 2020-03-27

Last Posted Date: 2024-07-26

Lead Sponsor: Celgene

Target Recruit Count: 184

Registration Number: NCT04324840

Locations: 🇳🇱
Local Institution - 400, Rotterdam, Netherlands
🇳🇴
Local Institution - 600, Oslo, Norway
🇳🇱
Local Institution - 408, Leiden, Zuid-Holland, Netherlands

and more 26 locations

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Enasidenib

First Posted Date: 2020-03-17

Last Posted Date: 2020-03-17

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT04310527

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: CC-90009
Radiation: [14C]

First Posted Date: 2020-03-05

Last Posted Date: 2021-12-17

Lead Sponsor: Celgene

Target Recruit Count: 8

Registration Number: NCT04297124

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: CC-99677
Drug: Methotrexate
Drug: Itraconazole
Drug: Midazolam
Drug: Sulfasalazine
Drug: Rifampin
Drug: Digoxin
Drug: Metformin
Drug: Rosuvastatin

First Posted Date: 2020-02-13

Last Posted Date: 2021-08-18

Lead Sponsor: Celgene

Target Recruit Count: 48

Registration Number: NCT04268394

Locations: 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy